Clinical grade lentiviral vector purification and quality control requirements
- 15 March 2022
- journal article
- review article
- Published by Wiley in Journal of Separation Science
- Vol. 45 (12) , 2093-2101
Abstract
Lentiviral vectors have been proven to be a powerful tool in gene therapies that includes the ability to perform long‐term gene editing in both dividing and non‐dividing cells. In order to meet the rising demand for clinical‐grade lentiviral vectors for future clinical trials and requirements by regulatory agencies, new methods and technologies were developed, including the rapid optimization of production and purification processes. However, gaps still exist in achieving ideal yields and recovery rates in large‐scale manufacturing process steps. The downstream purification process is a critical step required to obtain a sufficient quantity and high‐quality lentiviral vectors products, which is challenged by the low stability of the lentiviral vector particles and large production volumes associated with the manufacturing process. This review summarizes the most recent and promising technologies and enhancements used in the large‐scale purification process step of lentiviral vector manufacturing and aims to provide a significant contribution towards the achievement of providing sufficient quantity and quality of lentiviral vectors in scalable processes.Keywords
Funding Information
- National Natural Science Foundation of China (22174100, 21405006)
This publication has 76 references indexed in Scilit:
- Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich SyndromeScience, 2013
- New developments in lentiviral vector design, production and purificationExpert Opinion on Biological Therapy, 2013
- Biosafety Features of Lentiviral VectorsHuman Gene Therapy, 2013
- Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugationJournal of Translational Medicine, 2011
- Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltrationBMC Biotechnology, 2011
- Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy ApplicationHuman Gene Therapy, 2011
- Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfectionBlood, 2009
- Downstream processing of oncoretroviral and lentiviral gene therapy vectorsBiotechnology Advances, 2006
- Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor CellsPLOS Biology, 2004
- Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primatesBlood, 2002